Nifty
Sensex
:
:
10656.20
35474.51
-107.20 (-1.00%)
-300.37 (-0.84%)

Pharmaceuticals & Drugs

Rating :
77/99

BSE: 530239 | NSE: SUVEN

245.30
-2.60 (-1.05%)
20-Nov-2018 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  246.85
  •  249.80
  •  244.00
  •  247.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  227585
  •  558.27
  •  337.80
  •  161.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,147.70
  • 20.44
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,154.39
  • 0.61%
  • 3.41

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.00%
  • 4.92%
  • 22.41%
  • FII
  • DII
  • Others
  • 0.12%
  • 1.64%
  • 10.91%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.15
  • 4.15
  • 7.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 29.60
  • 1.23
  • 12.45

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.38
  • 1.91
  • 16.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.54
  • 20.19
  • 20.18

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.29
  • 4.19
  • 3.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.27
  • 13.34
  • 13.78

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Net Sales
-
625.26
543.53
499.52
520.86
117.28
111.92
88.08
63.62
Net Sales Growth
-
15.04%
8.81%
-4.10%
344.12%
4.79%
27.07%
38.45%
 
Cost Of Goods Sold
-
150.91
147.06
162.64
177.61
44.18
42.04
30.66
19.80
Gross Profit
-
474.35
396.47
336.88
343.25
73.10
69.88
57.42
43.83
GP Margin
-
75.86%
72.94%
67.44%
65.90%
62.33%
62.44%
65.19%
68.89%
Total Expenditure
-
427.07
414.46
398.18
361.40
104.61
95.57
77.29
55.10
Power & Fuel Cost
-
33.56
31.50
29.32
28.04
7.95
6.34
5.77
5.13
% Of Sales
-
5.37%
5.80%
5.87%
5.38%
6.78%
5.66%
6.55%
8.06%
Employee Cost
-
61.27
52.17
35.64
31.75
12.25
9.53
7.37
6.25
% Of Sales
-
9.80%
9.60%
7.13%
6.10%
10.45%
8.52%
8.37%
9.82%
Manufacturing Exp.
-
148.78
153.86
139.49
95.91
29.74
27.89
25.17
16.36
% Of Sales
-
23.79%
28.31%
27.92%
18.41%
25.36%
24.92%
28.58%
25.72%
General & Admin Exp.
-
20.66
19.45
22.48
20.14
8.38
7.53
5.85
5.27
% Of Sales
-
3.30%
3.58%
4.50%
3.87%
7.15%
6.73%
6.64%
8.28%
Selling & Distn. Exp.
-
8.57
7.46
6.73
5.17
2.06
2.15
1.58
2.17
% Of Sales
-
1.37%
1.37%
1.35%
0.99%
1.76%
1.92%
1.79%
3.41%
Miscellaneous Exp.
-
3.31
2.95
1.88
2.77
0.05
0.10
0.88
0.12
% Of Sales
-
0.53%
0.54%
0.38%
0.53%
0.04%
0.09%
1.00%
0.19%
EBITDA
-
198.19
129.07
101.34
159.46
12.67
16.35
10.79
8.52
EBITDA Margin
-
31.70%
23.75%
20.29%
30.61%
10.80%
14.61%
12.25%
13.39%
Other Income
-
23.27
21.09
19.62
8.58
3.18
1.46
0.82
1.54
Interest
-
4.63
5.68
5.88
4.71
5.06
3.03
1.65
0.82
Depreciation
-
21.31
21.41
17.50
11.78
4.44
4.01
3.46
3.23
PBT
-
195.53
123.07
97.58
151.55
6.36
10.76
6.49
6.01
Tax
-
71.84
35.88
25.74
42.80
-1.99
-0.51
0.11
3.61
Tax Rate
-
36.74%
29.15%
26.38%
28.24%
-31.29%
-4.74%
1.69%
60.07%
PAT
-
123.69
87.19
71.85
108.75
8.35
11.26
6.39
2.41
PAT before Minority Interest
-
123.69
87.19
71.85
108.75
8.35
11.26
6.39
2.41
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
19.78%
16.04%
14.38%
20.88%
7.12%
10.06%
7.25%
3.79%
PAT Growth
-
41.86%
21.35%
-33.93%
1,202.40%
-25.84%
76.21%
165.15%
 
Unadjusted EPS
-
9.70
6.84
5.61
9.04
0.72
3.91
2.55
0.96

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Shareholder's Funds
767.41
667.00
595.28
559.31
106.39
101.52
90.21
81.18
Share Capital
12.73
12.73
12.73
12.73
11.57
5.76
5.00
5.00
Total Reserves
754.68
654.27
582.56
546.59
94.82
95.76
85.21
76.18
Non-Current Liabilities
29.36
28.21
40.54
86.43
57.06
46.78
30.83
33.03
Secured Loans
0.25
22.65
37.08
55.09
54.62
41.49
23.68
19.81
Unsecured Loans
1.14
3.29
4.56
6.36
0.00
0.00
0.00
0.00
Long Term Provisions
3.69
2.84
2.39
2.27
0.00
0.00
0.00
0.00
Current Liabilities
221.04
208.05
210.62
127.39
35.08
24.95
21.98
21.55
Trade Payables
56.82
37.94
35.60
43.89
20.14
11.87
11.63
11.97
Other Current Liabilities
30.27
46.14
48.18
42.45
0.63
1.06
0.29
0.27
Short Term Borrowings
24.94
30.49
24.16
28.24
0.00
0.00
0.00
0.00
Short Term Provisions
109.01
93.49
102.68
12.81
14.32
12.02
10.07
9.31
Total Liabilities
1,017.81
903.26
846.44
773.13
198.53
173.25
143.02
135.76
Net Block
307.73
305.72
305.35
171.95
109.77
95.62
82.77
74.14
Gross Block
375.68
348.92
325.15
290.52
141.20
120.47
101.64
88.59
Accumulated Depreciation
67.95
43.19
19.80
118.57
31.43
24.86
18.87
14.45
Non Current Assets
351.30
322.10
318.79
291.31
115.72
105.60
89.53
84.55
Capital Work in Progress
24.74
9.72
7.20
107.01
3.66
5.02
2.67
3.31
Non Current Investment
0.07
0.07
0.07
0.00
2.29
4.96
4.09
7.09
Long Term Loans & Adv.
18.55
6.39
6.16
10.89
0.00
0.00
0.00
0.00
Other Non Current Assets
0.20
0.20
0.00
1.46
0.00
0.00
0.00
0.00
Current Assets
666.50
581.16
527.66
476.98
82.79
67.60
53.43
51.14
Current Investments
278.73
300.89
0.05
0.04
0.00
0.00
0.00
0.00
Inventories
139.47
92.51
83.46
81.81
24.40
22.90
22.74
19.31
Sundry Debtors
61.54
45.83
53.56
40.17
35.59
16.14
14.99
18.62
Cash & Bank
20.83
9.17
241.40
279.69
3.04
9.78
1.37
2.57
Other Current Assets
165.95
32.89
40.22
41.22
19.77
18.79
14.33
10.63
Short Term Loans & Adv.
115.32
99.87
108.96
34.06
14.93
14.33
9.70
8.81
Net Current Assets
445.46
373.11
317.04
349.59
47.71
42.65
31.45
29.58
Total Assets
1,017.80
903.26
846.45
773.14
198.53
173.24
143.02
135.78

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 08
Mar 07
Mar 06
Mar 05
Cash From Operating Activity
69.94
109.17
67.50
3.94
16.24
5.51
2.11
PBT
195.53
123.07
97.58
6.36
10.76
6.49
5.79
Adjustment
10.32
12.91
10.98
11.22
6.54
6.56
3.97
Changes in Working Capital
-92.37
7.90
-14.36
-12.96
0.46
-6.52
-6.95
Cash after chg. in Working capital
113.47
143.88
94.20
4.63
17.75
6.54
2.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-43.54
-34.71
-26.70
-0.69
-1.51
-1.03
-0.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-0.61
-310.64
-38.63
-16.20
-20.46
-9.45
-4.11
Net Fixed Assets
-41.78
-26.29
-187.49
-19.37
-21.18
-13.51
Net Investments
-15.06
-342.87
-14.91
2.67
-0.87
4.00
Others
56.23
58.52
163.77
0.50
1.59
0.06
Cash from Financing Activity
-57.70
-30.39
-68.07
5.52
12.62
2.73
-7.51
Net Cash Inflow / Outflow
11.63
-231.86
-39.20
-6.74
8.40
-1.20
-9.51
Opening Cash & Equivalents
8.69
240.55
279.75
9.78
1.37
2.57
12.09
Closing Cash & Equivalent
20.32
8.69
240.55
3.04
9.78
1.37
2.57

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Mar 04
Book Value (Rs.)
60.29
52.40
46.77
43.56
9.19
35.21
9.01
8.11
8.16
ROA
12.88%
9.97%
8.87%
22.38%
4.49%
7.12%
4.58%
1.82%
4.11%
ROE
17.25%
13.81%
12.50%
32.91%
8.04%
11.76%
7.46%
2.96%
6.49%
ROCE
26.12%
18.19%
15.43%
37.93%
7.51%
10.74%
7.59%
6.73%
8.95%
Fixed Asset Turnover
1.73
1.62
1.63
2.42
0.92
1.02
0.95
0.80
0.68
Receivable days
31.34
33.32
34.19
26.51
78.68
50.16
68.08
82.03
76.64
Inventory Days
67.71
58.98
60.29
37.16
71.95
73.54
85.16
87.39
85.28
Payable days
38.57
33.17
35.72
32.74
57.23
45.77
52.98
65.92
70.34
Cash Conversion Cycle
60.48
59.13
58.77
30.93
93.40
77.93
100.27
103.49
91.59
Total Debt/Equity
0.04
0.11
0.14
0.20
0.51
0.41
0.26
0.24
0.25
Interest Cover
43.25
22.65
17.61
33.18
2.26
4.55
4.93
8.30
11.60

News Update:


  • Suven Life Sciences - Quarterly Results
    14th Nov 2018, 16:04 PM

    Read More
  • Suven Life Sciences secures product patents in Australia, Hong Kong
    13th Nov 2018, 10:21 AM

    The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively

    Read More
  • Suven Life Sciences secures product patents in Israel, Japan
    6th Nov 2018, 10:29 AM

    The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively

    Read More
  • Suven presenting positive Pre-clinical, Phase-1 clinical data at Neuroscience 2018
    5th Nov 2018, 10:41 AM

    Neuroscience is the annual meeting of the Society for Neuroscience and more than 30 thousand Neuro-Scientists from all over the world

    Read More
  • Suven Life Sciences completes patient enrollment for Phase 2 POC study of SUVN-502
    25th Oct 2018, 12:38 PM

    This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients

    Read More
  • Suven to participate in 11th clinical trials on Alzheimer's disease in Spain
    23rd Oct 2018, 10:40 AM

    SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate Alzheimer’s disease, a novel triple combination treatment approach

    Read More
  • Suven Life Sciences secures product patents in Canada, Sri Lanka
    25th Sep 2018, 11:24 AM

    The granted claims of the patents include the class of selective H3 and 5-HT6 compounds

    Read More
  • Suven Life Sciences secures product patents in New Zealand, Sri Lanka
    14th Sep 2018, 11:25 AM

    The granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively

    Read More
  • Suven Life Sciences secures product patents in China, Eurasia
    29th Aug 2018, 11:31 AM

    Patents are valid through 2034

    Read More
  • Suven Life Sciences secures product patents in Canada, USA
    23rd Aug 2018, 10:33 AM

    The secured product patents are valid through 2034

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.